Taken together, these observations suggest that ibrutinib inhibits Aβ-activated EGFR (off-target of ibrutinib), which suppresses GSK-3β phosphorylation at Y216 and subsequently attenuates tau hyperphosphorylation in a mouse model of AD. This evidence concerns the gene MAPT and Alzheimer disease.